Different Modes of Retrovirus Restriction by Human APOBEC3A and APOBEC3G In Vivo

PLoS Pathogens

Volumn 10, Issue 5, 2014, Pages

  Stavrou, Spyridon ^a   Crawford, Daniel ^a   Blouch, Kristin ^a   Browne, Edward P ^b   Kohli, Rahul M ^a   Ross, Susan R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3A PROTEIN, HUMAN; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; PROTEIN; VIF PROTEIN; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

3T3 CELL LINE; ANIMAL; C57BL MOUSE; CELL CULTURE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; PHYSIOLOGY; RETROVIRIDAE; RETROVIRUS INFECTION; TRANSGENIC MOUSE; VIROLOGY; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CELLS, CULTURED; CYTIDINE DEAMINASE; HIV-1; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NIH 3T3 CELLS; PROTEINS; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIRUS ASSEMBLY; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84901674110     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004145     Document Type: Article

References (79)

1. Zheng YH, Jeang KT, Tokunaga K, (2012) Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology 9: 112.
2. Duggal NK, Emerman M, (2012) Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol 12: 687-695.
3. Ko TP, Lin JJ, Hu CY, Hsu YH, Wang AH, et al. (2003) Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution. J Biol Chem 278: 19111-19117.
4. Bishop KN, Holmes RK, Sheehy AM, Malim MH, (2004) APOBEC-mediated editing of viral RNA. Science 305: 645-645.
5. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defense by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
6. Harris RS, Sheehy AM, Craig HM, Malim MH, Neuberger MS, (2003) DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol 4: 641-643.
7. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14: 1392-1396.
8. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, et al. (2004) Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol 337: 585-596.
9. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH, (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231.
10. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, et al. (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucl Acids Res 35: 7096-7108.
11. Wang X, Ao Z, Chen L, Kobinger G, Peng J, et al. (2012) The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J Virol 86: 3777-3786.
12. Sheehy AM, Gaddis NC, Malim MH, (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
13. Stopak K, de Noronha C, Yonemoto W, Greene WC, (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12: 591-601.
14. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR, (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 23: 2451-2458.
15. Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, et al. (2014) Multiple APOBEC3 Restriction Factors for HIV-1 and One Vif to Rule Them All. J Mol Biol 426: 1220-1245.
16. Schrofelbauer B, Chen D, Landau NR, (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 101: 3927-3932.
17. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, et al. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: 21-31.
18. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR, (2006) APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucl Acids Res 34: 89-95.
19. Muckenfuss H, Hamdorf M, Held U, Perkovic M, Lower J, et al. (2006) APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem 281: 22161-22172.
20. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, et al. (2006) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 16: 480-485.
21. Peng G, Greenwell-Wild T, Nares S, Jin W, Lei KJ, et al. (2007) Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110: 393-400.
22. Aguiar RS, Lovsin N, Tanuri A, Peterlin BM, (2008) Vpr.A3A chimera inhibits HIV replication. J Biol Chem 283: 2518-2525.
23. Koning FA, Goujon C, Bauby H, Malim MH, (2011) Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J Virol 85: 13448-13452.
24. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, et al. (2011) APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog 7: e1002221.
25. Ooms M, Krikoni A, Kress AK, Simon V, Munk C, (2012) APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J Virol 86: 6097-6108.
26. Thielen BK, McNevin JP, McElrath MJ, Hunt BV, Klein KC, et al. (2010) Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem 285: 27753-27766.
27. Ribeiro AC, Maia e Silva A, Santa-Marta M, Pombo A, Moniz-Pereira J, et al. (2005) Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol 79: 823-833.
28. Jonsson SR, LaRue RS, Stenglein MD, Fahrenkrug SC, Andresdottir V, et al. (2007) The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS One 2: e893.
29. Lee J, Choi JY, Lee HJ, Kim KC, Choi BS, et al. (2011) Repression of porcine endogenous retrovirus infection by human APOBEC3 proteins. Biochem Biophys Res Commun 407: 266-270.
30. Groom HC, Yap MW, Galao RP, Neil SJ, Bishop KN, (2010) Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci USA 107: 5166-5171.
31. Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois MA, Neuberger MS, et al. (2008) Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol 82: 10998-11008.
32. Low A, Okeoma CM, Lovsin N, de las Heras M, Taylor TH, et al. (2009) Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virol 385: 455-463.
33. Okeoma CM, Lovsin N, Peterlin BM, Ross SR, (2007) APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445: 927-930.
34. Narvaiza I, Linfesty DC, Greener BN, Hakata Y, Pintel DJ, et al. (2009) Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog 5: e1000439.
35. Turelli P, Mangeat B, Jost S, Vianin S, Trono D, (2004) Inhibition of hepatitis B virus replication by APOBEC3G. Science 303: 1829.
36. Nguyen DH, Gummuluru S, Hu J, (2007) Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 81: 4465-4472.
37. Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, et al. (2006) Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43: 1364-1374.
38. Vartanian JP, Guetard D, Henry M, Wain-Hobson S, (2008) Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320: 230-233.
39. Suspene R, Aynaud MM, Koch S, Pasdeloup D, Labetoulle M, et al. (2011) Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J Virol 85: 7594-7602.
40. Cullen BR, (2006) Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 80: 1067-1076.
41. Okeoma CM, Petersen J, Ross SR, (2009) Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J Virol 83: 3029-3038.
42. Okeoma CM, Low A, Bailis W, Fan HY, Peterlin BM, et al. (2009) Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection. J Virol 83: 3486-3495.
43. Okeoma CM, Huegel AL, Lingappa J, Feldman MD, Ross SR, (2010) APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe 8: 534-543.
44. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, et al. (2008) Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321: 1343-1346.
45. Langlois MA, Kemmerich K, Rada C, Neuberger MS, (2009) The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J Virol 83: 11550-11559.
46. Sanchez-Martinez S, Aloia AL, Harvin D, Mirro J, Gorelick RJ, et al. (2012) Studies on the restriction of murine leukemia viruses by mouse APOBEC3. PLoS ONE 7: e38190.
47. MacMillan AL, Kohli RM, Ross SR, (2013) APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J Virol 87: 4808-4817.
48. Rulli SJ Jr, Mirro J, Hill SA, Lloyd P, Gorelick RJ, et al. (2008) Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol 82: 6566-6575.
49. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
50. Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, et al. (2004) APOBEC3G targets specific virus species. J Virol 78: 8238-8244.
51. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K, (2007) Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 4: 61.
52. Rulli K, Lenz J, Levy LS, (2002) Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus. J Virol 76: 2363-2374.
53. Ardavin C, Ferrero I, Azcoitia I, Anjuere F, Diggelman H, et al. (1999) B cell response after MMTV infection: extrafollicular plasmablasts represent the main infected population and can transmit viral infection. J Immunol 162: 2538-2545.
54. Dzuris JL, Golovkina TV, Ross SR, (1997) Both T and B cells shed infectious mouse mammary tumor virus. J Virol 71: 6044-6048.
55. Finstad SL, Rosenberg N, Levy LS, (2007) Diminished potential for B-lymphoid differentiation after murine leukemia virus infection in vivo and in EML hematopoietic progenitor cells. J Virol 81: 7274-7279.
56. Courreges MC, Burzyn D, Nepomnaschy I, Piazzon I, Ross SR, (2007) Critical role of dendritic cells in mouse mammary tumor virus in vivo infection. J Virol 81: 3769-3777.
57. Balkow S, Krux F, Loser K, Becker JU, Grabbe S, et al. (2007) Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naive T cells, and favors expansion of regulatory T cells. Blood 110: 3949-3958.
58. Stavrou S, Nitta T, Kotla S, Ha D, Nagashima K, et al. (2013) Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex. Proc Natl Acad Sci USA 110: 9078-9083.
59. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15: 166-170.
60. Bishop KN, Holmes RK, Malim MH, (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 80: 8450-8458.
61. Holmes RK, Koning FA, Bishop KN, Malim MH, (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation: Comparisons with APOBEC3G. J Biol Chem 282: 2587-2595.
62. Harel J, Rassart E, Jolicoeur P, (1981) Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virus. Virol 110: 202-207.
63. Ross SR, (1997) Mouse mammary tumor virus and the immune system. Adv Pharmacol 39: 21-46.
64. Szymczak AL, Vignali DA, (2005) Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther 5: 627-638.
65. An P, Bleiber G, Duggal P, Nelson G, May M, et al. (2004) APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 78: 11070-11076.
66. Reddy K, Winkler CA, Werner L, Mlisana K, Abdool Karim SS, et al. (2010) APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 24: 195-204.
67. Bizinoto MC, Leal E, Diaz RS, Janini LM, (2011) Loci polymorphisms of the APOBEC3G gene in HIV type 1-infected Brazilians. AIDS Res Hum Retroviruses 27: 137-141.
68. Browne EP, Littman DR, (2008) Species-specific restriction of apobec3-mediated hypermutation. J Virol 82: 1305-1313.
69. Rulli SJ Jr, Mirro J, Hill SA, Lloyd P, Gorelick RJ, et al. (2008) Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol 82: 6566-6575.
70. Sheehy AM, Gaddis NC, Malim MH, (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
71. Stopak K, de Noronha C, Yonemoto W, Greene WC, (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12: 591-601.
72. Krisko JF, Martinez-Torres F, Foster JL, Garcia JV, (2013) HIV restriction by APOBEC3 in humanized mice. PLoS Pathog 9: e1003242.
73. Turelli P, Liagre-Quazzola A, Mangeat B, Verp S, Jost S, et al. (2008) APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice. J Virol 82: 6585-6590.
74. Landry S, Narvaiza I, Linfesty DC, Weitzman MD, (2011) APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep 12: 444-450.
75. Suspene R, Aynaud MM, Guetard D, Henry M, Eckhoff G, et al. (2011) Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc Natl Acad Sci USA 108: 4858-4863.
76. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92.
77. Fan H, Chute H, Chao E, Feuerman M, (1983) Construction and characterization of Moloney murine leukemia virus mutants unable to synthesize glycosylated gag polyprotein. Proc Natl Acad Sci USA 80: 5965-5969.
78. Portis JL, McAtee FJ, Kayman SC, (1992) Infectivity of retroviral DNA in vivo. J Acquir Immune Defic Syndr 5: 1272-1273.
79. Rassa JC, Meyers JL, Zhang Y, Kudaravalli R, Ross SR, (2002) Murine retroviruses activate B cells via interaction with Toll-like receptor 4. Proc Natl Acad Sci USA 99: 2281-2286.